CD40L (Ruplizumab); Human IgG1 Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-CD40L (Ruplizumab); Human IgG1 antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD40L (Ruplizumab); Human IgG1 |
| Clone | [hu5c8] |
| Host Species | n/a |
| Reactive Species | human |
| Isotype | IgG1, kappa |
| Format | Protein A purified |
| Size | 0.2 mg |
| Concentration | n/a |
| Applications | Block; Flow Cytometry (FC/FACS) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Monoclonal antibody to detect CD40L in human samples. Cytokine that binds to CD40/TNFRSF5. Costimulates T-cell proliferation and cytokine production. Its cross-linking on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and CD28 costimulation. Induces the activation of NF-kappa-B and kinases MAPK8 and PAK2 in T-cells. Induces tyrosine phosphorylation of isoform 3 of CD28. Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4. Involved in immunoglobulin class switching. The antibody binds specifically to CD40L; a surface receptor expressed on activated T cells which acts as a costimulatory molecule to trigger |
| Immunogen | Immunogen: Human CD40L |
| Other Names | [CD40 ligand; tumour necrosis factor ligand superfamily member 5; TNFSF5; CD154; tumour necrosis factor related activation protein; TRAP], [CD40LG] |
| Gene, Accession # | [CD40L], Gene ID: 959, NCBI: NP_000065.1, UniProt: P29965 |
| Catalog # | MBS845972 |
| Price | $655 |
| Order / More Info | CD40L (Ruplizumab); Human IgG1 Antibody from MYBIOSOURCE INC. |
| Product Specific References | n/a |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies